Maxime Dely – Simple Transfusion or Red Cell Exchange: Two Techniques, Two Philosophies of Care
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, posted on LinkedIn:
”Simple transfusion or red cell exchange: two techniques, two philosophies of care.
When we think of a blood transfusion, we usually imagine a straightforward act – giving red blood cells to correct anemia or improve oxygenation.
But in certain cases – sickle cell disease, polycythemia vera, severe malaria, or intoxications – there’s another option: red cell exchange by apheresis.
Instead of adding more blood, we gradually replace the patient’s red cells with healthy donor cells using an apheresis machine.
The total blood volume remains constant, and the process is precise, controlled, and personalized for each patient.
The benefits are clear:
- Rapid correction of abnormal red cell proportions.
- No iron overload – a common issue with repeated transfusions.
- Improved blood viscosity, reducing vaso-occlusive risks.
- Above all, a tailored, patient-specific approach – precision transfusion medicine.
Of course, this technique requires specialized expertise, equipment, and teamwork. But it represents where medicine is heading: more targeted, safer, and more human.
Behind every red cell exchange stands a dedicated team – nurses, physicians, and biologists – turning advanced technology into meaningful care.”

Keep up with Hemostasis Today.
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines
-
Nov 15, 2026, 20:50Asmaa Beltagy: Efficacy and Safety of Eltrombopag in SLE-Associated Immune Thrombocytopenia
-
Nov 15, 2026, 16:29Jean-Jacques Kiladjian: 20 Years of Interferon-Alpha Research in Myeloproliferative Neoplasms
-
Nov 15, 2026, 16:21Sukanto Paul: Why Platelet Transfusion Is Generally Avoided in TTP
-
Nov 15, 2026, 16:14Ahmad G. Alzahrani: Major Bleeding and Anticoagulant Reversal
-
Nov 15, 2026, 16:05Sabine Eichinger: Is Recurrence Risk After Provoked VTE Really Low?